PRMT5 Inhibition Has a Potent Anti-Tumor Activity Against Adenoid Cystic Carcinoma of Salivary Glands

The study explores the potential of PRMT5 inhibitors, specifically PRT543 and PRT811, as treatments for adenoid cystic carcinoma (ACC) of the salivary glands. PRMT5 was identified as a promising target due to its role in regulating oncogenic processes. The inhibitors demonstrated significant anti-tumor activity by reducing ACC cell proliferation and MYB/MYC expression in preclinical models. Combining PRT811 with lenvatinib further enhanced growth inhibition, suggesting potential clinical benefits. The study involved 62 patients and highlighted the need for further research due to the absence of patient survival data and complete mutational profiles. Overall, the findings support the development of PRMT5 inhibitors as targeted therapies for ACC.